Beamr video compression achieves up to 50% improvement for AVs
Investing.com -- Shares of Immunovant, Inc. (NASDAQ:IMVT) fell by 4%, while Roivant (NASDAQ:ROIV) experienced a 2% decline in today’s trading session. The dip came unexpectedly following the announcement of positive results from their respective studies on batoclimab for Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), despite an initial surge of 6%.
Immunovant reported that in the Phase 3 MG study, batoclimab met its primary endpoint. Participants receiving 680mg weekly showed a significant 5.6 point improvement in MG-ADL at week 12, compared to a 4.7 point improvement for the 340mg dosing and a 3.6 point improvement in the placebo group. The study highlights included notable differences between dosing arms, especially for deeper response thresholds. Safety and tolerability were consistent with previous studies of the drug.
In the Phase 2b CIDP study, initial data showed a significant 1.8 point improvement in the aINCAT score at week 12, with an 84% responder rate among patients whose IgG was reduced by ≥ 70%. Other CIDP scales also showed meaningful improvements.
Despite these positive outcomes, Immunovant has indicated that it does not currently intend to seek regulatory approval for batoclimab in MG or CIDP. Instead, the company is focused on advancing IMVT-1402, a potentially best-in-class anti-FcRn that may deliver deeper and more durable clinical responses for patients with autoimmune conditions. The final decision on regulatory submissions for batoclimab will be deferred until the ongoing Phase 3 studies in thyroid eye disease are complete.
The stock movement today reflects the market’s complex reaction to the news, balancing the positive study results with the strategic decisions regarding drug development and regulatory pathways. Investors and analysts will be closely monitoring the upcoming webcast for additional information that may impact the companies’ future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.